Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

PARKE-DAVIS CI-934 GRAM POSITIVE ACTIVITY IN VITRO may be superior to other drugs in the new crop of quionolone antimicrobials, company researchers suggested in presentations to the Oct. 8-10 Interscience Conference on Antimicrobial Agents and Chemotherapy in Washington, D.C. At the meeting, the firm's M. A. Cohen, et al., reported the results of comparative in vitro minimum inhibitory concentration (MIC) tests "against 229 bacterial isolates representing over 63 common pathogenic species." The comparative tests included another quinolone, ofloxacin, "because it represented the best gram positive quinolone we knew of before CI-934," Cohen said. Against 19 strains of methicillin-resistant and methicillin-susceptible strains of Staphylococcus aureus, CI-934's overall "activity was superior to that of ofloxacin, erythromycin, oxacillin and vancomycin," Cohen reported. Tested against 25 strains of Streptococci, erythromycin had the leading inhibitory rate, he said. However, CI-934 "was superior to penicillin G and cefazolin." In studies of 66 Enterobacteriaceae strains, CI-934 and ofloxacin were "comparable" and both "outperformed ampicillin and the combination of sulfamethoxazole and trimethoprim," he explained. The broad spectrum anti-bacterial is headed for human testing in the near future. At a recent meeting with security analysts, Warner-Lambert Pharmaceutical Div. President Jerry Weisbach, MD, said CI-934 will enter clinical trials "shortly." Weisbach added that the firm intends to position the drug for outpatient use. Preclinical data indicate the drug is active orally and parenterally. CI-934 will be Parke-Davis' second quinolone to enter clinical trials. Another compound, enoxacin, which is licensed from Dainippon, is currently undergoing Phase III testing. Overall, Cohen reported, "based in MIC values, CI-934 is highly potent v. a variety of common gram positive pathogens including staphlococci, beta-hemolytic [streptococci] (Mansfield Groups A, B, and C), pneumococcus, Group D [Streptococci] (enterococcal as well as non-enterococcal strains), Viridans streptococci, Listeria monocytogenes. The drug is also highly potent against gonococcus and Haemophilus influenzae, against Enterobacteriaceae and against anaerobes, for the most part excluding the Bacteroides fragilis group." In addition, he said, bactericidal studies indicate activity "against both gram positive and gram negative bacteria."

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts